Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImpedimedASX:IPD +20.00% EV-to-EBITDA is -1.32 as of Jul. 15, 2026. The stock has 6 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Impedimed ranks worse than 195694.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Impedimed's enterprise value is A$21.02 Mil.
Impedimed's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.97 Mil. Therefore, Impedimed's EV-to-EBITDA for today is -1.32.
The historical rank and industry rank for Impedimed's EV-to-EBITDA or its related term are showing as below:
ASX:IPD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.49 Med: -4.19 Max: -0.1
Current: -1.31
During the past 13 years, the highest EV-to-EBITDA of Impedimed was -0.10. The lowest was -18.49. And the median was -4.19.
ASX:IPD's EV-to-EBITDA is ranked worse than 100% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.2
vs ASX:IPD: -1.31
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Impedimed (ASX:IPD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Impedimed's share price for today is A$0.006.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Impedimed's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Impedimed's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impedimed EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Impedimed's EV-to-EBITDA falls into.
Impedimed's current Enterprise Value is A$21.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impedimed (ASX:IPD) has a EV-to-EBITDA of -1.32 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Impedimed. According to the industry distribution chart, Impedimed ranks #999999 out of 511 companies in the Medical Devices & Instruments industry.
Is Impedimed's EV-to-EBITDA too high?
Impedimed's current EV-to-EBITDA is -1.32. Based on the distribution chart, Impedimed ranks #999999 out of 511 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Impedimed's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #999999 out of 511 companies for EV-to-EBITDA. This places Impedimed in the lower half of its industry. The industry median EV-to-EBITDA is 14.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Impedimed. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current EV-to-EBITDA is -1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 92.5% below its estimated fair value. The current EV-to-EBITDA is -1.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current EV-to-EBITDA is -1.32 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 
